参考文献/References:
[1] Bressoud A, Schwab BZ. Thalidomide: (re)discovery of a not very dear old molecule[J]. Rev Med Suisse Romande, 2003, 123 (4):238-40.
[2] Singhal S, Mehta J. Thalidomide in cancer[J]. Biomed Pharmacother, 2002, 56(1): 4-12.
[3] 翟羽,吕占军.反应停对小鼠肝癌细胞H22移植瘤生长的影响[J].癌症,2003,22(12):1301-6.Zhai Y.Lu ZJ.Effect of thalidomide on tumor growth in mouse hepatoma H22 model[J].Ai Zheng,2003,22(12):1301-6.
[4] 许启泰,杜钢军,陈百泉.美蓝的抗肿瘤作用[J].中国药理学通报,2002,18(3):352-3.Xu QT, Du GJ, Chen BQ. Antitumor action of methylene blue[J].Chin Pharmacol Bull, 2002, 18(3): 352-3.
[5] Myoung H, Hong SD, Kim YY, et al. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma[J]. Cancer Lett,2001, 163(2): 191-200.
[6] 杜钢军,林海红,许启泰托盘根提取物对不同细胞的影响[J].中国药科大学学报,2001,32(6):468-70.Du GJ, Lin HH, Xu QT. Effect of ethanol extract of roots of rubus crataegifolius on tumor cells[J]. J Chin Pharm Univ, 2001, 32(6):468-70.
[7] Raje N, Kenneth C. Thalidomide and immunomodulatory drugs as cancer therapy[J]. Oncology, 2002, 14(6): 635-40.
[8] D’Amato RJ, Loughman MS, Flynn E. Thalidomide is an inhibitor of angiogenesis[J]. Proc Natl Acad Sci USA, 1994, 91(9): 4082-5.
[9] 平宝红,陈琪,周淑云,等.反应停治疗老年难治性多发性骨髓瘤1例报告[J].第一军医大学学报,2002,22(10):954.Ping BH,Chen Q,Zhou SY,et al.Treatment of old refractory multiple myeloma withthalidomide:report of one case[J].J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2002,22(10):954.
[10] 杨义明,杜钢军,宋华勇,等沙利度胺治疗难治性多发性骨髓瘤的临床研究[J].临床荟萃,2005,20(2):97-8.Yang YM,Du GJ,Song HY,et al.Clinical study on thalidomide in multiple myeloma[J].Clin Focus,2005,20(2):97-8.
[11] 李峰敏,王玉荣,徐建民.反应停诱导骨髓瘤细胞株(KM3)凋亡的初步研究[J].中国临床医学,2002,9(1):9-11.Li FM, Wang YR, Xu JM. Induction of apoptosis by thalidomide in KM3 myeloma cell line[J]. Clin Med J Chin, 2002, 9(1): 9-11.
[12] Kenyon BM, Browne F, D’Amato RJ. Effects of thalidomide and related metabolites in a mouse comeal model of neovascularization[J]. Exp Eye Res, 1997, 64(6): 971-8.
[13] Rajkumar Sv, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma[J]. Mayo Clin Proc, 2000,75(9): 897-901.
[14] Karrow NA, Guo TL, Zhang LX, et al. Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study[J]. Int Immunopharmacol, 2003, 3(10-11): 1447-56.
[15] 杨义明,杜钢军,林海红,等.反应停对HL-60细胞马利兰耐药的逆转作用[J].郑州大学学报(医学版),2005,40(2):300-2.Yang YM, -Du GJ, Lin HH, et al. Reverse effect of thalidomide on myleran-resistant HL-60 cells[J]. J Zhengzhou Univ (Med Sci),2005, 40(2): 300-2.
[16] Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives[J]. Leukemia Res, 2004, 28(4):325-32.
相似文献/References:
[1]陈耿臻,韩慧,许铭炎,等. 重组腺病毒ADV-TK 基因的构建及其对肝癌细胞的杀伤作用[J].南方医科大学学报,2010,(08):1887.
CHEN Geng-zhen,HU Hui,XU Ming-yan,et al. Construction of recombinant adenovirus containing TK gene and its effect against human liver cancer cells[J].Journal of Southern Medical University,2010,(08):1887.
[2]陈建发,李宇华,陈引香,等.Apollon siRNA提高肝癌细胞化疗敏感性的实验研究[J].南方医科大学学报,2011,(10):1701.
[3]凌志海,孙权权,张耀伟,等.吉西他滨增强肝癌HepG2细胞体外辐射敏感性的机制研究[J].南方医科大学学报,2011,(12):1993.
[4]季锡清,李朝龙,杨进城,等.血流阻断的缺血预处理技术在肝癌切除术中的应用[J].南方医科大学学报,2004,(01):66.
JI Xi-qing,LI Chao-long,YANG Jin-cheng,et al.Application of ischemic preconditioning before hepatic vascular exclusion for resection of hepatocellular carcinoma[J].Journal of Southern Medical University,2004,(08):66.
[5]王素珍,孟维静,安洪庆,等.基于倾向指数匹配法的肝癌病人疗效评价[J].南方医科大学学报,2012,(09):1234.
[6]玉艳红,原彤彤,黄力毅,等.外周血单核细胞hFgl2蛋白表达与不同临床类型肝病的关系[J].南方医科大学学报,2013,(03):436.
[7]戴小珍,熊新,王兰,等.CXCR7-shRNA慢病毒载体对人肝癌细胞生长及侵袭能力的抑制作用[J].南方医科大学学报,2013,(07):994.
[8]曲凯,林婷,魏吉超,等.Cisplatin induces cell cycle arrest and senescence via upregulating P53 and P21 expression in HepG2 cells[J].南方医科大学学报,2013,(09):1253.
[9]赵素容,张媛媛,吴成柱,等.3-溴丙酮酸增强肝癌细胞对顺铂敏感性的作用[J].南方医科大学学报,2014,(01):25.
[10]周陈杰,宫绪萌,蔡理全,等.改良的从肝硬化到产生肝癌的大鼠模型[J].南方医科大学学报,2014,(04):497.